Wired News - Catalent Acquires Juniper Pharma
LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want access to our free research report on Catalent, Inc. (NYSE: CTLT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CTLT as the Company's latest news hit the wire. On July 03, 2018, the Company announced that it has inked a deal to acquire all of the outstanding shares of Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR) ("Juniper"), including its Nottingham, UK-based Juniper Pharma Services division, for $11.50 per share in cash. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Catalent and Juniper Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=CTLT
www.active-investors.com/registration-sg/?symbol=JNP
Deal Details
The transaction represents a total equity value of approximately $139.6 million on a fully-diluted basis, and a premium of 59.7% to Juniper's unaffected share price on January 30, 2018.
Following the tender offer, Catalent plans to acquire the remainder of the Juniper shares at the same price through a merger with a newly formed wholly-owned subsidiary of Catalent.
The acquisition, expected to close in Q3 2018, is subject to certain customary closing conditions, including that a majority of Juniper's shares are tendered into the offer.
Strategic Benefits
The acquisition of Juniper will expand and strengthen Catalent's offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing. The deal will also complement its integrated global clinical and commercial supply network. Juniper's nearly 150 employees have deep scientific expertise in formulation development and supply, and will augment Catalent's current portfolio of solid-state screening, pre-formulation, formulation, analytical, and bioavailability enhancement solutions, including the development of spray-dried dispersions, with integrated development, analytical, and clinical manufacturing co-located in its Nottingham facility.
Catalent will continue to support Juniper's CRINONE® (progesterone gel) franchise marketed by Merck KGaA outside of the US.
Juniper's Scientific Expertise in Early-Phase Product Development will Provide Better Treatments to Patients
Jonathan Arnold, President of Catalent Oral Drug Delivery, stated that Juniper's proven solutions and capabilities will further support Catalent's strategic goal to be the most comprehensive partner for pharmaceutical innovators. Arnold added that Juniper's scientific expertise in early-phase product development and supply will help the Company's customers unlock the full potential of their molecules, and provide better and faster treatments to patients.
Reports suggest that post announcement of the news, shares of Juniper surged.
Catalent's Offer to Acquire Juniper Recognizes the Value of Juniper's Businesses, Juniper Pharma Services and CRINONE
Commenting on the acquisition, Alicia Secor, President and Chief Executive Officer (CEO) of Juniper, mentioned that the transaction is the culmination of a diligent and extensive process to pursue strategic alternatives in order to maximize shareholder value. Secor added that Catalent's offer to acquire Juniper recognizes the value of Juniper's businesses, Juniper Pharma Services and CRINONE.
About Catalent, Inc.
Founded in 2007 and headquartered in Somerset, New Jersey, Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. Catalent employs over 11,000 people across five continents, and generated over $2 billion in annual revenues in FY17.
About Juniper Pharmaceuticals, Inc.
Based in Boston, Massachusetts, Juniper is focused on developing therapeutics that addresses unmet medical needs in women's health. Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the US.
Stock Performance Snapshot
July 05, 2018 - At Thursday's closing bell, Catalent's stock was marginally up 0.83%, ending the trading session at $42.36.
Volume traded for the day: 766.88 thousand shares.
Stock performance in the last month - up 7.73%; previous three-month period - up 6.59%; past twelve-month period - up 20.07%; and year-to-date - up 3.12%
After yesterday's close, Catalent's market cap was at $5.64 billion.
Price to Earnings (P/E) ratio was at 47.92.
The stock is part of the Healthcare sector, categorized under the Drugs - Generic industry. This sector was up 1.0% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
SOURCE: Active-Investors
